Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q1 2021 · 10-Q
Revenue$22.81M$22.81M+31.0% vs Q1 2020 Net Income-$4.28M-$4.28MN/M vs Q1 2020 EPS Diluted-$0.17-$0.17N/M vs Q1 2020 Gross Profit$19,785,000+31.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
Operating Cash Flow-$3,631,000N/M Free Cash Flowderived-$4,381,000N/M Margins · derivedGross margin86.7%+0.5 pt vs Q1 2020
Operating margin-18.8%−24.7 pt vs Q1 2020
Net margin-18.8%−22.0 pt vs Q1 2020
ended Mar 31, 2021 · filed May 10, 2021 · 40 d after period end